A Trend in Acquired Drug Resistances of Tuberculosis Patients Registered in Health Centers from 1981 to 2004

Chulhun-L CHANG; Eun-Yup LEE; Soon-Kew PARK; Seok-Hoon JEONG; Young-Kil PARK; Yong-Woon CHOI; Hee-Jin KIM; Woo-Jin LEW; Gill-Han BAI.
Tuberculosis and Respiratory Diseases ; : 619-624, 2005.
Artículo en Ko | WPRIM | ID: wpr-162062

Documentos relacionados

  1. [Complications of intravesical BCG therapy].
  2. Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.
  3. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
  4. <i>Mycobacterium tuberculosis</i> Genotypes and Drug Susceptibility Test Results from Timor-Leste: A Pilot Study.
  5. Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.
  6. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
  7. A high-throughput LC-MS/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma.
  8. Tackling quantitative polymorphic analysis through fixed-dose combination tablets production. Pyrazinamide polymorphic assessment.
  9. Validation and application of a quantitative LC-MS/MS assay for the analysis of first-line anti-tuberculosis drugs, rifabutin and their metabolites in human breast milk.
  10. Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.